Epileptic seizure

FDA approves new treatment for adults with partial-onset seizures

Retrieved on: 
Thursday, November 21, 2019
RTT, Anticonvulsants, Epileptic seizure, Clinical medicine, Epilepsy, Medicine, Health, GABAA receptor positive allosteric modulators, Lacosamide, Seizure types

SILVER SPRING, Md., Nov. 21, 2019 /PRNewswire/ --The U.S. Food and Drug Administration today approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults.

Key Points: 
  • SILVER SPRING, Md., Nov. 21, 2019 /PRNewswire/ --The U.S. Food and Drug Administration today approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults.
  • This approval provides an additional needed treatment option for people with this condition."
  • Seizures can cause uncontrolled movements, abnormal thinking or behavior, and abnormal sensations.
  • The safety and efficacy of XCOPRI to treat partial-onset seizures was established in two randomized, double-blind, placebo-controlled studies that enrolled 655 adults.

Empatica Announces EmbracePlus: NASA Medical Quality in a Down-to-Earth Smart Watch

Retrieved on: 
Tuesday, November 19, 2019
Articles, Economy, Collaborative finance, Crowdfunding, Entrepreneurship, Financial technology, Translational Research Institute, Epileptic seizure, Technology

BOSTON, Nov. 19, 2019 /PRNewswire/ -- On November 19th, 2019, Empatica is announcing EmbracePlus , their new smart watch built in partnership with TRISH, the Translational Research Institute for Space Health.

Key Points: 
  • BOSTON, Nov. 19, 2019 /PRNewswire/ -- On November 19th, 2019, Empatica is announcing EmbracePlus , their new smart watch built in partnership with TRISH, the Translational Research Institute for Space Health.
  • 50 years ago, on November 19th, 1969, Apollo 12 made a precision landing on the surface of the moon.
  • The brand new EmbracePlus will provide the highest quality measures for long-term medical sensing while functioning reliably and robustly, despite harsh and challenging environments.
  • Five years ago on November 19, 2014, Empatica launched a successful crowdfunding campaign to create the first medical smart watch to detect seizures, Embrace.

Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology

Retrieved on: 
Wednesday, November 13, 2019
RTT, Anticonvulsants, Clinical medicine, Organ systems, Medicine, GABAA receptor positive allosteric modulators, Sodium channel blockers, Epileptic seizure, Epilepsy, Lacosamide, Lennox–Gastaut syndrome

The results of the study demonstrated that adjunctive treatment with cenobamate produced significant reductions in seizures compared to placebo.

Key Points: 
  • The results of the study demonstrated that adjunctive treatment with cenobamate produced significant reductions in seizures compared to placebo.
  • "This is the firstpublication showing the results of a randomized, controlled clinical trialof cenobamate in adults with uncontrolled focal seizures," said Gregory L.Krauss, MD, professor of neurology at Johns Hopkins University and lead author of the study.
  • "The results demonstrated significant dose-related reductions in seizure frequency with cenobamate during the maintenance phase compared to placebo.
  • Encouragingly, a highnumber of patients had zero seizures during the maintenance phase in the 200 mg and 400 mg groups."

Embrace2 by Empatica Used by NEC in Revolutionary Employee Health Study

Retrieved on: 
Wednesday, November 13, 2019
Companies, Economy of Japan, Medicine, Epileptic seizure, RTT, NEC, Generalized tonic–clonic seizure, Epilepsy, Companies, Economy of Japan, Medicine, Epileptic seizure, RTT, NEC, Generalized tonic–clonic seizure, Epilepsy

Embrace2 is a smartband that is currently widely used as a research device, and for the monitoring of tonic-clonic seizures in people suffering from epilepsy.

Key Points: 
  • Embrace2 is a smartband that is currently widely used as a research device, and for the monitoring of tonic-clonic seizures in people suffering from epilepsy.
  • NEC uses the device's sensors in a study to estimate chronic stress by analyzing the physiological signals of voluntary participants.
  • NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world.
  • The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society.

Embrace2 by Empatica Used by NEC in Revolutionary Employee Health Study

Retrieved on: 
Wednesday, November 13, 2019
Companies, Economy of Japan, Medicine, Epileptic seizure, RTT, NEC, Generalized tonic–clonic seizure, Epilepsy, Companies, Economy of Japan, Medicine, Epileptic seizure, RTT, NEC, Generalized tonic–clonic seizure, Epilepsy

Embrace2 is a smartband that is currently widely used as a research device, and for the monitoring of tonic-clonic seizures in people suffering from epilepsy.

Key Points: 
  • Embrace2 is a smartband that is currently widely used as a research device, and for the monitoring of tonic-clonic seizures in people suffering from epilepsy.
  • NEC uses the device's sensors in a study to estimate chronic stress by analyzing the physiological signals of voluntary participants.
  • NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world.
  • The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society.

Engage Therapeutics to Present at the Stifel 2019 Healthcare Conference

Retrieved on: 
Tuesday, November 12, 2019
RTT, Clinical medicine, Medicine, GABAA receptor positive allosteric modulators, Epileptic seizure, Health, Causes of seizures, Epilepsy, Alprazolam, Anticonvulsant

SUMMIT, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- /PRNewswire/ Engage Therapeutics, Inc ., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, will participate in the Stifel 2019 Healthcare Conference in New York City.

Key Points: 
  • SUMMIT, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- /PRNewswire/ Engage Therapeutics, Inc ., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, will participate in the Stifel 2019 Healthcare Conference in New York City.
  • Gregory T. Mayes, President and CEO of Engage Therapeutics, will present a company overview on Wednesday, Nov. 20, at 3:35 p.m.
  • Engage Therapeutics is developing Staccato alprazolam for the immediate termination of an ongoing epileptic seizure.
  • Engage Therapeutics is based in Summit, N.J. For additional information please see www.engagetherapeutics.com .

Cadence Neuroscience Secures $15 Million in Series A Financing for Commercialization of Epilepsy Therapy Licensed from Mayo Clinic

Retrieved on: 
Wednesday, November 6, 2019
Branches of biology, Medicine, Clinical medicine, Electrophysiology, Neurophysiology, Neurotechnology, Epilepsy, Electroencephalography, Neurology, Epileptic seizure

REDMOND, Wash., Nov. 6, 2019 /PRNewswire/ --Cadence Neuroscience announced today that it has secured $15 million in Series A financing.

Key Points: 
  • REDMOND, Wash., Nov. 6, 2019 /PRNewswire/ --Cadence Neuroscience announced today that it has secured $15 million in Series A financing.
  • The round was led by JAZZ Venture Partners, with additional support being provided by Mayo Clinical Ventures, Mayo Benefactors Innovation Fund, and the Epilepsy Foundation of America (EFA).
  • The therapy utilizes chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures.
  • Cadence Neuroscience is an early-stage company developing new medical device therapies for the treatment of epilepsy and other neurological disorders.

Le Bonheur Children's Hospital Launches Infantile Epilepsy Center

Retrieved on: 
Monday, November 4, 2019
Medicine, Clinical medicine, Health, Syndromes, Epileptic spasms, Le Bonheur Children's Hospital, Epileptic seizure, Le bonheur, Epilepsy

MEMPHIS, Tenn., Nov. 4, 2019 /PRNewswire/ --Le Bonheur Children's Hospital has launched an Infantile Epilepsy Center that focuses on the potentially devastating diagnosis of infantile spasms and other rare epilepsies that affect children under two-years-old.

Key Points: 
  • MEMPHIS, Tenn., Nov. 4, 2019 /PRNewswire/ --Le Bonheur Children's Hospital has launched an Infantile Epilepsy Center that focuses on the potentially devastating diagnosis of infantile spasms and other rare epilepsies that affect children under two-years-old.
  • "Infants are not just small children," said Sarah Weatherspoon, MD, an assistant professor of Pediatric Neurology at the University of Tennessee Health Science Center and Director of the Infantile Epilepsy Center at Le Bonheur Children's.
  • "The Infantile Epilepsy Center is an example of the culture of excellence we have built at Le Bonheur Children's," said Le Bonheur President and CEO Michael Wiggins.
  • The Infantile Epilepsy Center also uses other treatments such as anti-seizure medications, dietary therapy and epilepsy surgery to help control infantile epilepsy.

Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome

Retrieved on: 
Friday, October 25, 2019
Medicine, Organ systems, Epilepsy, Health, Lennox–Gastaut syndrome, Dravet syndrome, Sudden unexpected death in epilepsy, Generalized tonic–clonic seizure, Epileptic seizure, Epilepsy syndromes, Epilepsy-intellectual disability in females

These data continue to demonstrate the significant clinical impact Fintepla has shown in studies of Dravet syndrome patients, said Bradley Galer, M.D., Executive Vice President and Chief Medical Officer at Zogenix.

Key Points: 
  • These data continue to demonstrate the significant clinical impact Fintepla has shown in studies of Dravet syndrome patients, said Bradley Galer, M.D., Executive Vice President and Chief Medical Officer at Zogenix.
  • Dravet syndrome patients commonly experience generalized tonic-clonic seizures, which are often treatment resistant and have been identified as a major risk factor for SUDEP.
  • We believe that the apparent dose-response effect observed could suggest an important contribution of seizure control or drug effect on executive function in Dravet syndrome patients.
  • The Company anticipates top-line data for FINTEPLA in Lennox-Gastaut syndrome in the first quarter of 2020.

Neurelis Announces Three Poster Presentations At The Annual Meeting Of The Child Neurology Society

Retrieved on: 
Tuesday, October 22, 2019
Drugs, Psychoactive drugs, Health, RTT, GABAA receptor positive allosteric modulators, Chloroarenes, Lactams, Benzodiazepines, Diazepam, Epileptic seizure, Dose, Clinical trial

VALTOCO is a proprietary formulation of diazepam, incorporating the unique combination of a vitamin Ebased solution and Intravail transmucosal absorption enhancement technology.

Key Points: 
  • VALTOCO is a proprietary formulation of diazepam, incorporating the unique combination of a vitamin Ebased solution and Intravail transmucosal absorption enhancement technology.
  • In a long-term, open-label clinical trial, the safety of VALTOCO was evaluated: 190 patients were enrolled and 2,274 seizures were treated.
  • Approximately 92% of the seizures treated with a single dose of VALTOCO did not require a second dose within at least 24 hours.
  • Neurelis, Inc., is an innovation-driven neuroscience company providing a highly differentiated approach to target unmet medical needs.